News & Updates

Show Multimedia Only
Brolucizumab a viable alternative in proliferative diabetic retinopathy

Brolucizumab a viable alternative in proliferative diabetic retinopathy

02 May 2026 byJairia Dela Cruz

In the treatment of patients with proliferative diabetic retinopathy, brolucizumab outperforms panretinal laser photocoagulation in terms of preserving visual acuity, according to the international phase III CONDOR trial.

02 May 2026
Semaglutide may avert adult-onset epilepsy in patients with diabetes Semaglutide may avert adult-onset epilepsy in patients with diabetes

Semaglutide may avert adult-onset epilepsy in patients with diabetes

01 May 2026 byStephen Padilla

Treatment with semaglutide appears effective in reducing the risk of adult-onset epilepsy or seizures relative to sodium–glucose cotransporter-2 inhibitors (SGLT2i) and other glucose-lowering drugs (GLDs) in patients with type 2 diabetes mellitus (T2DM), according to a study presented at AAN 2026.

01 May 2026
Young-onset diabetes drives productivity losses in HK

Young-onset diabetes drives productivity losses in HK

24 Apr 2026 byChristina Lau

Young-onset diabetes (YOD) costs Hong Kong more than USD 400 million annually in productivity, researchers from the Chinese University of Hong Kong (CUHK) have reported.

24 Apr 2026